Appendix cancer differential diagnosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 30: | Line 30: | ||
! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ! colspan="8" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="5" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
|- | |- | ||
| colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | | colspan="5" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | ||
Line 108: | Line 107: | ||
| style="background: #F5F5F5; padding: 5px;" |[[Biopsy]] | | style="background: #F5F5F5; padding: 5px;" |[[Biopsy]] | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid tumor<sup>2</sup> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Carcinoid tumor<sup>2</sup> | ||
Line 141: | Line 139: | ||
'''Microscopic pathology:''' | '''Microscopic pathology:''' | ||
|[[Biopsy]] | |[[Biopsy]] | ||
|- | |- | ||
| colspan="2" |[[Ovarian cancer differential diagnosis|Ovarian cancer]] | | colspan="2" |[[Ovarian cancer differential diagnosis|Ovarian cancer]] | ||
| style="background: #F5F5F5; padding: 5px;" |+/- | | style="background: #F5F5F5; padding: 5px;" | +/- | ||
| style="background: #F5F5F5; padding: 5px;" |+/- | | style="background: #F5F5F5; padding: 5px;" | +/- | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
|<nowiki>+/-</nowiki> | |<nowiki>+/-</nowiki> | ||
| | | | ||
Line 153: | Line 150: | ||
* Dyspnea | * Dyspnea | ||
* GI disturbance | * GI disturbance | ||
| style="background: #F5F5F5; padding: 5px;" |+ | | style="background: #F5F5F5; padding: 5px;" | + | ||
| style="background: #F5F5F5; padding: 5px;" |+/- | | style="background: #F5F5F5; padding: 5px;" | +/- | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* [[Ascites]] | * [[Ascites]] | ||
Line 160: | Line 157: | ||
* Fever | * Fever | ||
* Pleural effusion | * Pleural effusion | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" |- | | style="background: #F5F5F5; padding: 5px;" | - | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* '''Depends on the underlying etiology''' | * '''Depends on the underlying etiology''' | ||
Line 186: | Line 183: | ||
* Adnexal mass | * Adnexal mass | ||
* Adenexal Cyst (simple or complex) | * Adenexal Cyst (simple or complex) | ||
* ovarian | * Except for [[Thecoma]], ovarian masses are generally hyperintense on T1 and hypo or isointense on T2 imaging | ||
* Fluid accumulation | * Fluid accumulation | ||
* Endometrial thickening | * Endometrial thickening | ||
Line 201: | Line 198: | ||
* calcification | * calcification | ||
| style="background: #F5F5F5; padding: 5px;" |N/A | |||
| style="background: #F5F5F5; padding: 5px;" |Depends on the tumor type. You may find the details [[Ovarian cancer differential diagnosis|here]]. | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Biopsy | |||
|- | |- | ||
| colspan="2" | | | colspan="2" | | ||
| | | | ||
| | | | ||
Line 227: | Line 223: | ||
|- | |- | ||
| colspan="2" | | | colspan="2" | | ||
| | | | ||
| | | | ||
Line 268: | Line 263: | ||
* Typically does not invade visceral organs or spread by [[lymphatic]] or hematogenous routes unlike mucinous carcinomatosis | * Typically does not invade visceral organs or spread by [[lymphatic]] or hematogenous routes unlike mucinous carcinomatosis | ||
| | | | ||
Characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. MRI has better sensitivity in detecting ascites fluid and mucocele. | |||
| | | | ||
* The echoes within pseudomyxoma peritonei are not mobile. | * The echoes within pseudomyxoma peritonei are not mobile. | ||
* Echogenic septations within the gelatinous ascites. | * Echogenic septations within the gelatinous ascites. | ||
* Scalloping of the [[hepatic]] and splenic margins | * Scalloping of the [[hepatic]] and splenic margins | ||
| | |18F-FDG [[PET scan]] | ||
| | | | ||
* Depending on [[WHO]]<nowiki/>classification, whether it's low or high grade with cellular atypia or acellular mucin. ( DPAM, PMCA) | * Depending on [[WHO]]<nowiki/>classification, whether it's low or high grade with cellular atypia or acellular mucin. ( DPAM, PMCA) | ||
Line 285: | Line 282: | ||
| | | | ||
* Diagnostic laparascopy/laparatomy | * Diagnostic laparascopy/laparatomy | ||
|- | |- | ||
| colspan="2" |Carcinoid syndrome | | colspan="2" |Carcinoid syndrome | ||
Line 329: | Line 325: | ||
* [[Endoscopic]] [[ultrasonography]] (EUS) | * [[Endoscopic]] [[ultrasonography]] (EUS) | ||
| | | | ||
| | | | ||
Line 373: | Line 368: | ||
|[[Tc-99m]] labeled anti-[[CD15]] [[antibodies]] | |[[Tc-99m]] labeled anti-[[CD15]] [[antibodies]] | ||
|Evidences of [[inflammation]] | |Evidences of [[inflammation]] | ||
|CT scan | |A combination of Imaging (ultrasonography or CT scan, while CT scan is more sensitive), physical exam and history | ||
[[Appendicitis diagnostic scoring|Alvarado Score]] | |||
|- | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
| | |||
|} | |} | ||
Revision as of 22:46, 8 February 2019
Appendix cancer Microchapters |
Diagnosis |
---|
Treatment |
Appendix cancer differential diagnosis On the Web |
American Roentgen Ray Society Images of Appendix cancer differential diagnosis |
Risk calculators and risk factors for Appendix cancer differential diagnosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
appendix cancer must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
appendix cancer must be differentiated from [[differential dx1], [differential dx2], and [differential dx3].
Differentiating appendix cancer from other Diseases
appendix cancer must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as [differential dx1], [differential dx2], and [differential dx3].
OR
appendix cancer must be differentiated from [differential dx1], [differential dx2], and [differential dx3].
OR
As appendix cancer manifests in a variety of clinical forms, differentiation must be established in accordance with the particular subtype. [Subtype name 1] must be differentiated from other diseases that cause [clinical feature 1], such as [differential dx1] and [differential dx2]. In contrast, [subtype name 2] must be differentiated from other diseases that cause [clinical feature 2], such as [differential dx3] and [differential dx4].
Differentiating appendix cancer from other diseases on the basis of [symptom 1], [symptom 2], and [symptom 3]
On the basis [symptom 1], [symptom 2], and [symptom 3], appendix cancer must be differentiated from [disease 1], [disease 2], [disease 3], [disease 4], [disease 5], and [disease 6].
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||||||||
Abdominal pain | Change in girdle size | Change in bowel habits | Other symptoms | Abdominal mass | abdominal tenderness | Other physical examination findings | Urinary 5-hydroxyindoleacetic acid (5-HIAA) | Serum Chromogranin A (CgA) | Other lab findings | CT scan | MRI | Utrasounography | Other imaging modalities | |||||
Diarrhea | Constipation | |||||||||||||||||
Appendix cancer | Adenocarcinoma1 | +/- | -/+ | - | + |
|
- | - |
|
- | - |
|
|
|
|
Positron emission tomography (PET) | Gross pathology:
Microscopic pathology: |
Biopsy |
Carcinoid tumor2 | +/- | - | + | - |
|
- | - |
|
+ | + |
|
|
Gross pathology:
Microscopic pathology: |
Biopsy | ||||
Ovarian cancer | +/- | +/- | - | +/- |
|
+ | +/- |
|
- | - |
|
|
|
|
N/A | Depends on the tumor type. You may find the details here. |
| |
Pseudomyxoma peritonei | + | + | -/+ | -/+ | Bloating | - | + | Ascites
Shifting dullness |
- | - |
|
|
Characterized by a mass which is hypointense on T1-weighted MRI and hyperintense on T2-weighted MRI. MRI has better sensitivity in detecting ascites fluid and mucocele. |
|
18F-FDG PET scan |
|
| |
Carcinoid syndrome | -/+ | - | + | - | Flushing
Palpitation Dyspnea |
- | - |
|
+ | + |
|
Depends on the primary tumor location and type | Depends on the primary tumor location and type | Depends on the primary tumor location and type |
|
|||
Appendicitis 3 | LLQ / RRQ | - | -/+
|
+ | Nausea & vomiting,decreased appetite
Anorexia |
+/- | + |
|
- | - |
|
Appendiceal wall thickening /perforation
peri-appendiceal inflammation, fluid accumulation,fat stranding |
Increased fluid signal on T2 weighted sequence | Evidences of inflammation
|
Tc-99m labeled anti-CD15 antibodies | Evidences of inflammation | A combination of Imaging (ultrasonography or CT scan, while CT scan is more sensitive), physical exam and history | |
1 Adenocarcinomas usually present with appendicitis, barely they might present with Pseudomyxoma peritonei; meanwhile Pseudomyxoma peritonei is more prevalent in perforated mucocele, goblet cell tumor or high stages of adenocarcinoma.
2 Generally appendix carcinoids are asymptomatic, they were only become symptomatic if they metastasize to the liver, or in rare cases make an obstruction and present with appendicitis which is quit uncommon in appendiceal carcinoids compared to appendiceal adenocarcinoma. Any patient with carcinoid syndrome should be evaluated for appendix carcinoids.
3 Every patient with appendicitis should be evaluated for appendix cancer, 0.5 in 100 appendicitis cases are because of appendix cancer.